The study examined consecutive preterm neonates undergoing laser treatment of ROP in the neonatal intensive care unit. Twenty-two patients received morphine and 13 received fentanyl, and midazolam was also used when necessary. A change in ventilation status was observed in 45.46 percent of morphine patients and 15.39 percent of fentanyl patients, according to the report.
Apneic events were more common in the morphine group. The data suggests that continuous infusion with fentanyl is safer than morphine for preterm infants undergoing ROP laser therapy in the neonatal ICU.
Read the OSN SuperSite report on fentanyl.
Read more on anesthesia:
–ASA Responds to Study on Anesthesia Service Contract Compensation
–Involving Anesthesia in Transparency and ACOs: Q&A With Somnia Chief Medical Officer Dr. Rob Goldstein
–Non-Infiltrative Anesthetics Effective in Treating Transrectal Prostate Biopsy Pain
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
